Mainz Biomed shares rise 26.25% premarket after securing $6M funding for U.S. pancreatic tests and asset sales.

Mainz Biomed surged 26.25% in premarket trading following the announcement of a $6.0 million private placement with investor David Lazar, which will fund its strategic pivot to U.S. pancreatic cancer screening and asset sales. The financing, structured in two $3.0 million tranches, provides liquidity to address liabilities, stabilize operations, and support discussions for selling its colorectal cancer screening business while winding down its German subsidiary. Lazar’s appointment as Chairman further signals renewed leadership and strategic clarity. The move addresses operational challenges, reduces costs, and positions the company to focus on high-potential U.S. growth opportunities, directly aligning with the stock’s sharp premarket increase.